SOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea
Rhea-AI Summary
SOHM Inc. (OTCID:SHMN) has secured a new patent allowance in South Korea for its innovative gene-editing technology. The patent covers the company's ABBIE gene-editing platform, which combines dCas9 with retroviral integrases for targeted DNA sequence incorporation.
The approved technology, titled "CAS9 Retroviral Integrase and CAS9 Recombinase Systems," strengthens SOHM's global intellectual property portfolio, following previous successes in Europe. This advancement is particularly significant for developing next-generation allogeneic CAR-T therapies and regenerative medicine applications.
Positive
- Patent allowance in South Korea expands global IP portfolio
- Technology builds on previous successful patent approvals in Europe
- Platform shows potential for next-generation CAR-T therapies development
Negative
- None.
News Market Reaction
On the day this news was published, SHMN declined 33.33%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHINO HILLS, CALIFORNIA / ACCESS Newswire / September 15, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announce that it has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative technology entitled - "CAS9 Retroviral Integrase and CAS9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into a Genome of a Cell or Organism"
Patent Application No. 10-2024-7041475
This patent builds on our growing global IP portfolio around the ABBIE gene-editing platform, which fuses dCas9 with retroviral integrases. Dr. David Aguilar said.
Following earlier successes in Europe, this Korean allowance reinforces ABBIE's potential as a first-in-class solution for site-specific integration - a critical step toward developing next-generation allogeneic CAR-T therapies, regenerative medicine, and beyond.
At SOHM, we remain committed to building a global intellectual property estate that secures our innovations and drives partnerships worldwide.
For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc.
View the original press release on ACCESS Newswire
FAQ
What patent did SOHM (SHMN) receive approval for in South Korea?
How does SOHM's ABBIE gene-editing platform work?
What markets has SOHM (SHMN) secured patent protection in for its gene-editing technology?
What are the potential applications of SOHM's patented gene-editing technology?
